Lok Nayak Hospital is the national capital’s first COVID-19 only facility. Although Favipiravir was recently embraced in India by Glenmark Pharmaceuticals in the form of Fabiflu, this Delhi hospital has discontinued the use of the drug for COVID-19 patients. The well-known hospital has approved off label use of Ivermectin for early-stage COVID-19 patients, as well as Remdesivir, Tocilizumab, and plasma therapy.
Ivermectin
Although the hospital’s committee acknowledged that the only true evidence for Ivermectin comes from laboratory evidence as an inhibitor of the COVID-19 causative virus, it should be considered for hospitalized patients as it is A) cheap, B) available, and C) known to be safer than other drugs. Approved by the US FDA for parasitic infections, it’s only side effects are fever and skin rash. The hospital undoubtedly has been monitoring all the Ivermectin clinical trials now off the ground plus the significant building observational evidence from multiple countries. Lok Nayak Hospital suggests Ivermectin can help in limiting viral load and prevent severe disease progression.
That sounds right to me: "limiting viral load and prevent severe disease progression."
I was surprised that the semi-completed Bangladesh trial wasn't cited as a reason for going to ivermectin; India is paying attention to Bangladesh's interest in ivermectin.
Turns out that the Bangladesh trial is NOT completed, looking at ClinicalTrials.gov: results were submitted on July 27, but apparently they are still under review. There IS a preprint available, discussed here.
[-] TrumpLyftAlles | 2 points | Jul 05 2020 22:30:28
Lok Nayak Hospital is the national capital’s first COVID-19 only facility. Although Favipiravir was recently embraced in India by Glenmark Pharmaceuticals in the form of Fabiflu, this Delhi hospital has discontinued the use of the drug for COVID-19 patients. The well-known hospital has approved off label use of Ivermectin for early-stage COVID-19 patients, as well as Remdesivir, Tocilizumab, and plasma therapy.
Ivermectin
Although the hospital’s committee acknowledged that the only true evidence for Ivermectin comes from laboratory evidence as an inhibitor of the COVID-19 causative virus, it should be considered for hospitalized patients as it is A) cheap, B) available, and C) known to be safer than other drugs. Approved by the US FDA for parasitic infections, it’s only side effects are fever and skin rash. The hospital undoubtedly has been monitoring all the Ivermectin clinical trials now off the ground plus the significant building observational evidence from multiple countries. Lok Nayak Hospital suggests Ivermectin can help in limiting viral load and prevent severe disease progression.
That sounds right to me: "limiting viral load and prevent severe disease progression."
I was surprised that the semi-completed Bangladesh trial wasn't cited as a reason for going to ivermectin; India is paying attention to Bangladesh's interest in ivermectin.
Turns out that the Bangladesh trial is NOT completed, looking at ClinicalTrials.gov: results were submitted on July 27, but apparently they are still under review. There IS a preprint available, discussed here.
permalink